- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04069897
Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine (MiBlock)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Erling Tronvik, md phd
- Email: erling.tronvik@ntnu.no
Study Contact Backup
- Name: Tore Wergeland Meisingset, Md phd
- Phone Number: +47 47358725
- Email: tore.w.meisingset@ntnu.no
Study Locations
-
-
-
Bergen, Norway
- Recruiting
- Haukeland University Hospital, department of Neurology
-
Contact:
- Marte-Helene Bjørk, MD phd
-
Bodø, Norway
- Recruiting
- Nordland Hospital, department of Neurology
-
Contact:
- Karl Bjørnar Alstadhaug, md prof
-
Oslo, Norway
- Recruiting
- Nevroklinikken Universitetet i Oslo, Oslo Universitetssykehus HF
-
Contact:
- John-Anker Zwart, MD prof
-
Trondheim, Norway
- Recruiting
- St Olavs Hospital, Trondheim University Hospital
-
Contact:
- Erling Tronvik, md phd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
The participants must meet all of the inclusion criteria to participate in this study:
- Informed and written consent.
- Male or female, between 18 and 70 years of age
- Masters a Scandinavian language at level sufficient to fully understand the written and verbal study information
- Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria 1.3. for chronic migraine at time of inclusion
- Chronic migraine at least for a period of 1 year prior to inclusion
- Debut of episodic migraine before the age of 50, and chronic migraine before the age of 65.
The condition is pharmacologically refractory as defined in this study as insufficient treatment effect, contraindication(s) or intolerable side effect(s) of at least 3 medications from at least 2 of the following medication (drug) classes
- Beta-blockers
- RA(A)S-inhibitors
- Calcium-antagonists
- Antiepileptic drugs
- Tricyclic antidepressants
- Botulinum toxin A
- CGRP antagonists
- Subject has had no change in type, dosage or dose frequency of preventive headache medications < 3 months prior to baseline/screening, or a minimum of 5 half-lives, whichever is longer.
- Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during the whole study period.
- In the case of women of childbearing potential (WOCBP) they have to commit to highly effective contraception in a period of 4 weeks after injection (for details, confer section 4.3)
- Ability to understand study procedures and to comply with them for the entire length of the study
Exclusion Criteria:
All candidates meeting any of the exclusion criteria at baseline or visit 2 will be excluded from study participation:
- Allergy or hypersensitivity reactions to marcaine, lidocaine, xylocaine, adrenaline, any botulinum toxin or similar substances.
- Subject is unable to differentiate migraine from other concomitant headaches.
- Subject with secondary headache conditions, with the exception of medication overuse headache.
Non-responder in regular clinical practice to preventive medications from ≥6 of the following 7 drug classes:
- Beta-blockers
- RA(A)S-inhibitors
- Calcium-antagonists
- Antiepileptic drugs
- Tricyclic antidepressants
- Botulinum toxin A
- CGRP antagonists
- Subject has had a change in type, dosage or dose frequency of preventive headache medications < 3 months prior to baseline/screening, or a minimum of 5 half-lives, whichever is longer.
- Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period, eg. prior to IMP administration
- Botulinum toxin injections in the head and neck region, as part of migraine treatment or otherwise indicated on medical or cosmetic grounds, in the last 4 months before inclusion.
- The discontinuation of CGRP-antagonists within 3 months before study inclusion or 5 half-lives, whichever is longer,
- Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months before study inclusion or 5 half-lives, whichever is longer.
- Subject is currently participating or has participated in the last 3 months in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.
- Subject has had previous radiofrequency ablation, balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the trigeminal ganglion or any branch of the trigeminal nerve.
- Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the SPG.
- Subject has had blocks of short-acting anaesthetics of the SPG in the last 3 months.
- Subject is or has been treated with occipital nerve stimulation or deep brain stimulation.
- Ongoing abuse of drugs (including narcotics) or alcohol.
- More than 4 days of opioid use per month (including codeine and tramadol), and any use of barbiturates
- Treatment with pharmacological substances prior to SPG-injection that may interact with BTA (aminoglycosides, spectinomycin, neuromuscular blockers, both depolarizing agents (such as succinylcholine) or non-depolarizing (tubocurarine derivates), and anticholinesterases).
- Inadequate contraceptive use. Women of childbearing potential (WOCBP) who do not use highly effective contraception (HEC) or use other medication that may interact and/or otherwise reduce the efficacy of the contraceptive agents in use.
- Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary at the planned injection site that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.
- Facial anomaly or trauma which renders the procedure difficult.
- Subject currently has an active oral or dental abscess or a local infection at the site of injection based on present symptoms.
- Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past 6 months.
- Patients with comorbid psychiatric disorders with psychotic or other symptoms making compliance with the study protocol difficult, at the discretion of the investigator
- Patients exhibiting a high degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator
- Patients with disorders that severely inhibits lacrimation, at the discretion of the investigator
- Patients with previous ischemic cardiovascular and cerebrovascular disorder with, in the opinion of the investigator, a moderate to high risk of new ischemic episodes.
- Known infection or history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection.
- Subject has a history of bleeding disorders or coagulopathy, that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.
- Unable to stop antithrombotic medication e.g. platelet aggregation inhibitors and/or anticoagulation therapy, prior to procedure.
The patient cannot participate or successfully complete the study, in the opinion of their healthcare provider or the investigator, for any of the following reasons:
- mentally or legally incapacitated or unable to give consent for any reason
- in custody due to an administrative or a legal decision, under tutelage, or being admitted to a sanatorium or social institution
- has any other condition, which, in the opinion of the investigator, makes the patient inappropriate for inclusion in the study
- The patient is a study centre employee who is directly involved in the study or the relative of such an employee.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Botox injections towards SPG
Botulinum Toxin type A injections
|
Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun.
Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
Other Names:
|
Placebo Comparator: Controls
Placebo injections
|
0.5 ml Sodium Chloride (NaCl) 0.9% Braun.
Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the mean monthly headache days at weeks 5 - 8 post intervention
Time Frame: week 5 through week 8 in the post-injection period
|
Change from baseline to week 5-8 post-intervention in frequency of moderate to severe headache days.
Headache episodes that qualify is in the study defined as headache pain duration of ≥4 hours with a peak severity of moderate or severe intensity, or of any severity or duration if the subject takes and responds to rescue medication.
|
week 5 through week 8 in the post-injection period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events and serious adverse events in the treatment
Time Frame: week 1 through week 12 in the post-injection period
|
All adverse events and serious adverse events occurring in the 3 months follow up are registered in an electronic CRF.
Frequency of AE and SAE are compared between the placebo group and the treatment group
|
week 1 through week 12 in the post-injection period
|
Change from baseline in the mean monthly migraine days in the treatment
Time Frame: week 5 through week 8 in the post-injection period
|
A migraine day is defined as one day with headache pain fulfilling the ICHD3-criteria for migraine or probable migraine.
However, a headache duration of less than 4 hours is allowed if the subject takes and responds to triptans.
The frequency of headache days in the baseline period are compared to the frequency in week 5-8 post-intervention
|
week 5 through week 8 in the post-injection period
|
number of treatment responders (≥ 30% reduction in mean monthly headache days)
Time Frame: week 5 through week 8 in the post-injection period
|
A 30% treatment response is defined as a patient with a ≥ 30% reduction in frequency of headache days during weeks 5 - 8 post-intervention compared to baseline.
Headache is defined as in the primary outcome, i.e. moderate to severe headache days.
The number of responders is compared between the intervention and the placebo group
|
week 5 through week 8 in the post-injection period
|
Change from baseline in the mean monthly headache intensity in the treatment
Time Frame: week 1 through week 4, week 5 through week 8 and week 9 through week 12 in the post-injection period
|
Attack intensity is reported daily on a 11-point numerical response scale (NRS) in the electronic headache diary.
The mean attack intensity in week 5 - 8 post-intervention is compared to baseline in the active group versus the placebo group.
|
week 1 through week 4, week 5 through week 8 and week 9 through week 12 in the post-injection period
|
Change from baseline in the mean monthly occurrence of cumulative hours per 28 days of moderate/severe pain in the treatment
Time Frame: : week 1 through week 4, week 5 through week 8 and week 9 through week 12 in the post-injection period
|
The difference in hours with NRS ≥4 in the baseline period and weeks 1-4, 5-8 and 9-12 post injection are compared between the active group and the placebo group
|
: week 1 through week 4, week 5 through week 8 and week 9 through week 12 in the post-injection period
|
Change from baseline in the mean monthly number of days with rescue medication in the treatment
Time Frame: : week 1 through week 4, week 5 through week 8 and week 9 through week 12 in the post-injection period
|
Any use of rescue medication is reported in the headache diary every day.
The number of days with registered use of any headache related rescue medication in weeks 1-4, 5-8 and 9-12 post-intervention is compared to the baseline period
|
: week 1 through week 4, week 5 through week 8 and week 9 through week 12 in the post-injection period
|
Migraine specific quality of life questionnaire
Time Frame: week 8 and week 12 post-injection
|
Study participants will fill in the 6-question Headache impact test (HIT-6) at visit 1 (at inclusion) and at week 8 and week 12 postintervention.
Scores are compared between the placebo and the treatment group
|
week 8 and week 12 post-injection
|
Migraine specific quality of life questionnaire
Time Frame: week 8 and week 12 post-injection
|
Study participants will fill in the 14-question Migraine-Specific Quality-of-Life Questionnaire Version 2.1 (MSQ) at visit 1 (at inclusion) and at week 8 and week 12 postintervention.
Scores are compared between the placebo and the treatment group
|
week 8 and week 12 post-injection
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Geir Bråthen, md phd, St. Olavs Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Cysts
- Connective Tissue Diseases
- Mucinoses
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Ganglion Cysts
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- 2018/2161
- 2018-004053-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Disorders
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
Second Affiliated Hospital, School of Medicine,...SICHUAN CREDIT PHARMACEUTICAL CO., LTD.Not yet recruitingMigraine Without Aura | Migraine With AuraChina
Clinical Trials on Botulinum toxin type A
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Daewoong Pharmaceutical Co. LTD.Completed
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
Brazilan Center for Studies in DermatologyCompletedWrinkles in Frontal AreaBrazil
-
HugelCompletedBenign Masseteric HypertrophyKorea, Republic of
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
Medy-ToxCompletedCervical Dystonia
-
Seton Healthcare FamilyCompleted